10x Genomics, Inc. (NASDAQ:TXG) insider Bradford Crutchfield sold 17,000 shares of the firm’s stock in a transaction that occurred on Monday, April 12th. The shares were sold at an average price of $185.89, for a total value of $3,160,130.00. Following the completion of the transaction, the insider now owns 51,608 shares in the company, valued at approximately $9,593,411.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
TXG stock opened at $196.13 on Friday. The business has a fifty day moving average of $174.22 and a two-hundred day moving average of $161.05. The stock has a market cap of $21.33 billion, a price-to-earnings ratio of -145.28 and a beta of 1.39. 10x Genomics, Inc. has a 52-week low of $66.26 and a 52-week high of $203.20.
10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, February 16th. The company reported ($3.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($3.59). The business had revenue of $112.22 million for the quarter, compared to analyst estimates of $101.20 million. 10x Genomics had a negative return on equity of 19.98% and a negative net margin of 51.27%. As a group, analysts predict that 10x Genomics, Inc. will post -1.18 EPS for the current fiscal year.
Several equities analysts have recently weighed in on TXG shares. William Blair started coverage on 10x Genomics in a research report on Monday, March 22nd. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. increased their price target on 10x Genomics from $160.00 to $195.00 and gave the company an “overweight” rating in a report on Thursday, February 25th. Citigroup increased their price target on 10x Genomics from $195.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, February 25th. Cowen increased their price target on 10x Genomics from $155.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, February 25th. Finally, Morgan Stanley increased their price target on 10x Genomics from $145.00 to $215.00 and gave the company an “overweight” rating in a report on Thursday, February 25th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $183.70.
10x Genomics Company Profile
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Article: Lock-Up Period Expiration
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.